Dr Bostian joins Kemin from Mpex Pharmaceuticals, where he served as chief scientific officer and innovator of the company’s R&D platform.
Dr Bostian is expected to add significant biopharmaceutical industry, financial and operational experience to Kemin as the company continues to progress its clinical and preclinical programs. Dr Bostian earned his doctorate in biochemistry from the University of London.
Chris Nelson, president of Kemin Industries, said: “Kemin has completed the foundation work necessary to initiate key clinical activities in the US and Europe with our lead product, Anaeban. Keith will be instrumental in helping Kemin move this product forward aggressively in clinical trials and will also work with our research team to advance exciting new antimicrobial and anti-inflammatory candidates from our product pipeline.”